FDA and EMA grants orphan drug designation to recAP for the treatment of hypophosphatasia
9 June 2015 | By Victoria White
AM‐Pharma has announced that the FDA and EMA have both granted orphan designation status to recAP for the treatment of hypophosphatasia...